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Background: Transmissible Pseudomonas aeruginosa (Psa) strains such as the Liverpool Epidemic Strain (LES) are now widespread throughout
UK CF clinics: their susceptibility to antibiotics is therefore important. To study this, we compared antibiogram patterns of Psa strains in our CF
clinic over 5 years, looking at differences in resistance patterns between strains and changes to these over time.
Methods: The antibiograms of sputum samples between 2004 and 2008 from patients attending our centre were included. We compared Psa isolate
antibiotic resistance (to six anti-pseudomonal antibiotics) patterns for patients infected with LES with those infected with other Psa strains, both in
the total population in 2004 (125 patients) and 2008 (166 patients) and also longitudinally from annual review samples 2004 to 2008 in matched
and unmatched patient groups.
Results: LES exhibited signiﬁcantly more resistant isolates in 2004 (pb0.0001). There was an increase in antibiotic resistance in both LES and
other Psa strains over time (pb0.001). Cox proportional hazards analysis of both unmatched (n=125) and matched (n=56) patients in 2004
revealed that LES infected patients were more likely to develop antibiotic resistant isolates over time (hazard ratio 8.1, pb0.001). Fewer LES
isolates were classed as fully sensitive in both matched and unmatched groups at the end of study period (pb0.001).
Conclusion: This study shows a worrying trend in antibiotic resistance in the Psa isolates amongst patients chronically infected with LES. This
highlights the need to prevent cross infection through segregation and also the need to develop new strategies to treat these organisms.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pseudomonas aeruginosa; Antibiotic resistance; Liverpool Epidemic Strain (LES)1. Introduction
Chronic respiratory infection with Pseudomonas aeruginosa
(Psa) is the major cause of morbidity and mortality in CF [1,2],
where most deaths are due to end stage lung disease [3]. Treat-
ment of these infections involves combinations of intravenous
anti-Psa antibiotics, often given over prolonged periods, which
may encourage antibiotic resistance [4,5] and also enhance tox-
icity [6,7]. Furthermore, the recent emergence of Psa clones that⁎ Corresponding author. Tel.: +44 151 6001610; fax: +44 151 6001611.
E-mail address: martin.walshaw@lhch.nhs.uk (M.J. Walshaw).
1569-1993/$ -see front matter © 2011 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.11.004are highly transmissible between CF individuals and have been
shown to confer a worse prognosis [8–10] has complicated an-
timicrobial management.
Despite this, there have been no systematic studies looking
at antibiotic resistance over time in Psa in the CF community.
We therefore undertook a 5 year prospective study of the anti-
biotic resistance of Psa in patients attending a large adult CF
unit in the north-west of England, where there is a cohort of
individuals chronically infected with the Liverpool Epidemic
Strain (LES) of Psa, the most prevalent and important such
transmissible strain in the UK [11]. We looked for any differ-
ences in resistance patterns between strains and whether these
patterns have changed over time.by Elsevier B.V. All rights reserved.
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2.1. Patient cohorts
The Liverpool Adult CF Unit provides specialist services
for North Wales, Cheshire, Merseyside, and the Isle of Man:
a catchment of approximately 3 million people. All adult CF
patients have regular (at least bimonthly) sputum analysis for
Psa and to prevent cross-infection we have regularly genotyped
their strains for many years.
Patients who were chronically infected with Psa (defined by
at least 3 positive sputum samples within a 6 month period) [12]
formed the study population. For the purposes of this study,
patients additionally chronically infected with Burkholderia
cepacia complex and the only 2 with another known transmissi-
ble Psa strain (Midlands1) were excluded.
We compared Psa isolate antibiotic resistance patterns for
patients infected with LES with those infected with sporadic
Psa strains, from similar numbers of sputum samples taken in
2004 (125 patients, 91 LES) and 2008 (166 patients, 110 LES)
(Table 2) and also longitudinally from 2004 to 2008 in both
matched and unmatched patient groups (see below). For the
latter study, to standardise antibiogram selection the results
from the sputum sample closest to the anniversary of the
patient's birthday were used for each year.
2.2. Patient matching and statistical analysis
We used a propensity score [13] for LES group membership
in order to allow matching with the other group. This was deter-
mined without regard to outcome, using multivariable logistic
regression analysis with a full non-parsimonious model that in-
cluded all available patient characteristics, balancing all items
recorded that may relate to either systematic bias or simple
chance. This model yielded a C statistic of 0.78, indicating an
acceptable ability to differentiate between patients with or with-
out LES. We then used a macro (www2.sas.com/proceedings/
sugi29/165-29.pdf) to perform propensity-matching. Using
this model, in 2004 28 LES infected patients were matchedTable 1
Characteristics of 125 adult CF patients chronically infected with P. aeruginosa atten
Unmatched
Other Psa infection
(n=34)
LES Psa infection
(n=91)
Female (%) 43 53
Years since diagnosis 22 (16–27) 25 (23–29)
Age (years) 26 (21–34) 29 (24–36)
BMI 22 (20–24) 21 (19–23)
FEV1 (%) 64 (46–83) 64 (45–85)
Hospital admissions/year 4 (1–7) 8 (4–14)
Outpatient visits 33 (21–38) 36 (22–50)
Mean home iv days/year 7.3 7.9
Mean antibiotic resistance (%) 11.4 46.2
Categorical variables shown as percentage, comparisons made with χ2 test.
Continuous variables shown as median (25th–75th percentiles), comparisons madewith 28 infected with other Psa strains on clinical parameters
(age, sex, FEV1, BMI, time since diagnosis of CF, hospital
admissions, outpatient visits and baseline antibiotic resistance)
(Table 1). 2004 patient demographics are shown in Table 1.
Cox proportional hazards analysis was then used to deter-
mine changes in antibiotic resistance over time in both the
matched and unmatched groups.
Statistical significance was calculated using Fisher's exact
test and Chi squared tests with Yates correction: pb0.05 was
considered to be significant. Stata software version 2.0 was
used to analyse the data.3. Microbiological methods
3.1. Antibiotic susceptibility testing
Sputum samples were treated with equal quantities of sputa-
sol (oxoid), agitated at 200 rpm for 15 min at room temperature,
plated onto blood and chocolate agar and MacConkey agar, and
incubated at 37 °C. The plates were examined at 48 h for growth
of Psa colonies, and those with distinct morphotypes were fur-
ther cultured onto purity plates (chocolate agar). Each morpho-
logically different subtype (up to 5 per sample) was tested
for antibiotic susceptibility using BSAC guidelines [14] by the
disc diffusion method using the following: tazobactam/pipera-
cillin 85 μg, meropenem 10 μg, tobramycin10 μg, ciprofloxacin
5 μg, ceftazidime 30 μg and colistin sulphate 25 μg. The sizes
of the zones of inhibition (mm) were recorded and susceptibili-
ties were defined as per standard protocols. In total 9200 suscep-
tibility patterns were analysed.
Sputum samples with multiple morphotypes were judged to
be sensitive only if all morphotypes were sensitive to at least
two of the three classes of antibiotics tested (fluoroquinolones,
aminoglycosides, and beta-lactams/carbapenems). Strains were
defined as resistant if they were resistant to two of the three
classes of antibiotics [15] and pan-resistant if resistant to all
three classes of antibiotics. Isolates which exhibited intermedi-
ate resistance were considered resistant.ding the Liverpool Adult CF Centre in 2004 (unmatched and matched groups).
Matched (n=56)
p value Other Psa infection
(n=28)
LES Psa infection
(n=28)
p value
0.44 46 43 0.79
0.003 23 (18–29) 23 (21–26) 0.62
b0.01 25 (23–34) 27 (25–32) 0.18
0.08 21 (20–24) 22 (19–25) 0.80
0.88 63 (45~88) 77 (49–94) 0.45
b0.001 4 (1–7) 6 (3–10) 0.45
0.29 33 (21–36) 31 (17–49) 0.89
0.10 6.095 6.592 0.77
b0.001 14.3 10.7 >0.99
with Wilcoxon rank sum test.
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Oligonucleotide primers (Sigma-Genosys) used in PCR assays
were (PASS, PS21R, PS21F, LESF9F, LESF9R). DNA for PCR
amplification was prepared by making a suspension of a few col-
onies in 200 ml 5% Chelex-100 (Sigma) solution. After vigorous
mixing, the suspension was boiled for 5–10 min. Following
centrifugation, 150 ml of supernatant containing the DNA was
removed and stored at 220 °C. Typically, 1 ml of this DNA was
used directly in 25 μl volumes containing 1.25 unit Taq DNA
polymerase (Promega), 1× Taq Master (Helena Biosciences),
300 nM each primer, 1× Taq buffer, 2.5 μM MgCl2 and
100 μMnucleotides (dATP, dCTP, dGTP, dTTP). Amplifications
were carried out in an Eppendorf MasterCycler thermal cycler for
30 cycles consisting of 95 °C (1 min), chosen annealing tempera-
ture (1 min) and 72 °C (2 min), with an additional extension time
at 72 °C (10 min) following completion of the 30 cycles.
Psa and LES strains were identified using gel electrophoresis
looking for bands representing specific amplicons [16,17]. The
PA-SS, primer pair, specific for all Psa, yields an amplicon of
956 bp; the LES-specific primer pairs LESF9 and PS21 yield
amplicons of 461 bp and 364 bp respectively. PCR tests leading
to the PA-SS amplicon only were deemed LES-negative. Tests
leading to the presence of all three amplicons (PA-SS, LESF9
and PS21) were deemed LES-positive [18,19].
4. Results
4.1. Cross-sectional (unmatched) analysis of 2004 and 2008
cohorts
Analysis of the 2004 antibiograms showed that LES was more
resistant to ceftazidime, meropenem, piperacillin/tazobactam (all
pb0.001) and tobramycin (p=0.0001) than other Psa strains,
which in turn were more resistant to ciprofloxacin (pb0.002)
(Table 2). There was no resistance to colomycin in either group.
Overall, resistance was greater in the LES group (mean 18.1%)
than the other Psa group (mean 7.2%) (pb0.0001).
Analysis of the 2008 antibiograms showed that, compared to
2004, the overall mean antibiotic resistance increased in both
groups, but LES isolates became significantly more resistant
(pb0.0001) to all antibiotics except colomycin when comparedTable 2
Mean antibiotic resistance exhibited by LES Psa and other Psa isolates to six comm
2004 2008
Other Psa LES Psa p-value Other Psa
Total isolates (mean/patient) 303 (8.9) 685 (7.5) 0.47 580 (10.3)
Antibiotics %resistant %resistant %resistant
Ciprofloxacin 10.6 5.1 0.002 20.7
Ceftazidime 9.3 39.3 b0.0001 12.9
Tobramycin 3.0 10.5 0.0001 8.5
Colomycin 0.0 0.0 NS 2.8
Piperacillin/tazobactam 10.9 26.3 b0.0001 10.9
Meropenem 9.6 32.0 b0.0001 11.7to other Psa isolates (Table 2). Although in 2008 the other Psa
isolates showed increased mean resistance to ciprofloxacin
(10.6% vs 20.6%, p=0.0002), tobramycin (3.5 vs 8.5, p=
0.002) and colomycin (0 vs. 2.8, p=0.008), the LES isolates
had increased mean resistance to all six antibiotics used
(pb0.0001, except piperacillin/tazobactam p=0.01). The pro-
portions of resistant and pan-resistant strains were also signifi-
cantly higher in the LES group (see Fig. 1).
5. Longitudinal follow up of 2004 cohort
5.1. Unmatched cohort
The 125 patients in the 2004 cohort were followed for up to
5 years. Compared to the other Psa infected group, in terms of
baseline demographics the 91 patients chronically infected
with LES had a significantly higher age, mean antibiotic resis-
tance, time since diagnosis, and number of hospital admissions,
but no difference in sex, FEV1, BMI or number of outpatient
visits than those with other strains (see Table 1). Although
Cox proportional hazards analysis revealed that the LES
infected patients were more likely to develop antibiotic resistant
isolates over time (hazard ratio 8.1, pb0.001) (Table 3), as were
female CF patients (hazard ratio 1.56, p=0.045) and those with
a lower baseline FEV1 (hazard ratio 0.99, p=0.03), BMI and
time since the diagnosis of CF had no effect. At the end of the
5 year study period, there were 15 deaths and 3 transfers in pa-
tients with LES compared to 4 deaths and 1 transfer in those
with other Psa, and fewer LES group patient isolates were
classed as sensitive (9/73), compared to 25/31 in the other Psa
group (pb0.001) (see Fig. 1).
5.2. Matched cohort
Cox proportional hazards analysis of the 56 matched pa-
tients showed that LES infection (hazard ratio 6.1, pb0.001)
and lower baseline FEV1 (hazard ratio 0.98, p=0.03) increased
the likelihood of developing antibiotic resistant isolates over
time, whilst female sex, BMI or time since diagnosis had no
effect (Table 3). Even when adjusted for those clinical variables
predicting antibiotic resistance over time (age, sex, BMI,
FEV1, number of hospital admissions), LES infected patientsonly used antibiotics in 2004 and 2008.
Change in antibiotic resistance within Psa type
LES Psa p-value Other Psa 2004 v 2008
p-value
LES Psa 2004 v 2008
p-value
1196 (10.8) 0.89
%resistant
34.4 b0.0001 0.0002 b0.0001
58.1 b0.0001 NS b0.0001
35.1 b0.0001 0.002 b0.0001
3.6 NS 0.008 b0.0001
31.5 b0.0001 NS 0.01
43.1 b0.0001 NS b0.0001
n =              91 87 84 77 73 34 34 32 31 29
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Fig. 1. Prevalence of strain resistance in patients infected Psa followed from 2004 to 2008.
176 A. Ashish et al. / Journal of Cystic Fibrosis 11 (2012) 173–179developed more antibiotic resistant isolates during the 5 year
period (Fig. 2) (isolates classed as sensitive: LES infected
group [21.7%] versus other Psa infected group 22 [88.5%],
pb0.001).6. Discussion
For the first time to our knowledge we report a longitudinal
analysis of the antibiotic sensitivity patterns of P. aeruginosa
strains in chronically infected adult CF patients, including
those of the most common transmissible Psa strain in the UK,
LES. Our results demonstrate a high prevalence of antibiotic
resistance in Psa isolates in patients infected with LES and an
increased rate of acquisition of antibiotic resistance over time,
compared to other Psa strains.
Morbidity in patients with CF results from chronic suppura-
tive lung disease due to Psa, where repeated exacerbations
cause progressive lung damage leading to respiratory failure
and death in the majority of cases [3,20]. Up to 70% of adultTable 3
Cox proportional hazards for follow up antibiotic resistance in unmatched and
matched cohorts.
Variable Hazard ratio 95% conﬁdence
interval
p-value
Unmatched population (n=125)
LES 8.1 3.79 to 17.39 b0.001
Female 1.56 1.01 to 2.40 0.046
2004 BMI 1.00 0.93 to 1.07 0.99
2004 FEV1% 0.99 0.98 to 1.00 0.03
Time since diagnosis 1.00 0.97 to 1.00 0.82
Matched population (n=56)
LES 6.1 2.48 to 15.18 b0.001
Female 1.34 0.63 to 2.87 0.44
2004 BMI 1.12 0.98 to 1.27 0.09
2004 FEV1% 0.98 0.96 to 1.00 0.03
Time since diagnosis 1.00 0.96 to 1.05 0.76CF patients in the UK are chronically infected with Psa strains
[21]. Possibly due to selective antibiotic pressures, over time
these organisms undergo genotypic changes leading to the
emergence of treatment-resistant phenotypes: it was the appear-
ance of such a ceftazidime-resistant phenotype at a local paedi-
atric CF centre that led to the important discovery of the
original transmissible clone of Psa, LES, in 1996 [4]. LES is
widespread throughout UK CF units [11] and has also been dis-
covered elsewhere in the world [31]: it causes increased mor-
bidity, confers an increased healthcare burden, hastens clinical
deterioration [8,32] and can even spread to non-CF patients
[33] and across species [34]. Other transmissible strains have
since been discovered [9,22–30], and whilst some these have
shown increased virulence and antibiotic resistance and can
cause poorer clinical outcomes [8,9,27], these traits are not
universal [28–30].
Although a number of workers have shown the presence of re-
sistant isolates of transmissible strains in their patients [8,9,27,35]
none have demonstrated the presence of an excess of multiresis-
tant strains, and there have been no previous studies looking at
how the antibiotic sensitivity patterns of these epidemic strains
may change over time. We have a large cohort of LES-infected
CF patients, mainly inherited from paediatric practice, and this
has given us the opportunity to study this strain over a prolonged
period.
From our longitudinal study of 125 adult patients over
5 years, we have demonstrated that LES is not only more resis-
tant to antibiotics, but also has an enhanced rate of acquisition
of antibiotic resistance over time. We have previously shown
that chronic infection with LES causes increased hospitalisation
and IV antibiotic use [8]. However, this increased antibiotic re-
sistance may not simply be a reflection of repeated antibiotic
exposure leading to the emergence of resistance by natural se-
lection, since the effect was still seen following adjustment
for confounding factors, and antibiotic pressure only had a
weak effect. In keeping with accepted practice, we routinely
use at least two antipseudomonal drugs of different classes,
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sults of previous experience of those antibiotics, in consultation
with the patient. For those with sensitive strains, we rotate anti-
biotics to lessen the chances of resistance occurring.
The ability of Psa to mutate rapidly (hypermutate) in the
harsh environment of the CF lung that may give it a survival ad-
vantage [36,37], has also been suggested as an explanation for
the emergence of antibiotic resistance. However, although
hypermutable Psa strains can occur in up to 36% of CF patients
[37] we have found that hypermutability occurs less frequently
amongst LES isolates [38], suggesting that an alternative expla-
nation for its resistance to antibiotics is required.
Many isolates of LES, including those associated with trans-
mission to non-CF patients, exhibit an unusual quorum sensing
(QS) phenotype termed hypervirulence [39]. This phenotype
is characterised by a dysfunctional QS system, leading to over-
production of QS-regulated factors too early in the growth
phase. These hypervirulent isolates produce high levels of pyo-
cyanin and other QS-regulated exoproducts of relevance to CF
infections [38], and also exhibit greater killing activity against
Drosophila and C. elegans [40]. The phenotype has also been
linked to increased resistance to some antibiotics. Although
the mechanism for this is unknown, it may be related to up-
regulation of QS-regulated efflux pumps [38]. The hyperviru-
lence phenotype has not been identified in other Psa isolates,
whether in CF or other hosts. Hence, it seems feasible that it
might play a role in the success of this epidemic clone, the
greater morbidity associated with it, and the development of
resistance.
LES has also been found to possess an unstable genotype:
the subtypes within LES undergo deletions, insertions and rear-
rangement leading to significant phenotypic changes [42–44].
In a UK based survey looking at several transmissible strains,LES had greater microheterogeneity than other strains underlin-
ing its genetic variability [11].
There are limitations to our study. Firstly, we applied in vitro
antimicrobial sensitivity testing to organisms existing in the
special circumstances of the CF lung, where Psa lives in a com-
plex anaerobic bio-film community [41], and exhibits extensive
phenotypic divergence, including a mucoid form. Removing
these organisms and growing them in planktonic media in
aerobic conditions may not mirror sufficiently their natural
habitat. Furthermore, many different subtypes may exist within
the same sputum sample, each with a different antibiogram
[42–44]. Nevertheless, for the longitudinal study we standar-
dised our approach to the assessment of antibiotic resistance
by collecting samples at the same fixed time points for each pa-
tient, and utilising industry standard methodology [14] towards
antimicrobial testing. Furthermore, by using the same technique
for all Psa isolates (both LES and other strains) over a pro-
longed period the results produced are comparable. Secondly,
we cannot be sure that the increased antibiotic resistance in
the LES group does not simply reflect an increased use of anti-
biotics prior to the commencement of the study. Since most pa-
tients acquired LES in childhood, the length of infection could
not be ascertained, and this group had more hospital admis-
sions. It was for this reason that we used matched groups
with similar numbers of hospital admissions and outpatient
visits for the longitudinal study. Over the study period, in the
matched patients LES exhibited a much greater increase in an-
tibiotic resistance than other Psa strains, strongly suggesting
that this was not simply due to pre-existing resistance.
Even though individual sputum sensitivities may not be
representative of the true sensitivity in an infecting bacterial
population, using longitudinal data over 5 years gives us a
glimpse of the overall trends of the antibiotic resistance patterns
178 A. Ashish et al. / Journal of Cystic Fibrosis 11 (2012) 173–179in these patients, confirming the developing problem of antibi-
otic resistance in transmissible Psa in CF patients, particularly
in those with LES infection. Secondly, we only studied LES
and not other transmissible strains, so we cannot be sure that
our conclusions are valid for all such strains. However, LES
is the most prevalent transmissible strain in the UK and has
already spread to units elsewhere, so our findings will be of
relevance to all CF units.
In conclusion, this study shows a worrying trend in antibiotic
resistance in Psa isolates in the CF population, particularly
amongst those chronically infected with LES, which not only
exhibits more antibiotic resistance but also develops resistance
much more rapidly than other Psa strains. This highlights the
requirement for new antimicrobial therapies and the paramount
need to enforce stringent infection control and segregation
policies in CF units to limit the spread of transmissible Psa strains
to improve outcomes for CF patients.Conﬂict of interest
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